Status:
UNKNOWN
When Heparin Stopped for Anticoagulation During ECMO Decannulation
Lead Sponsor:
Second Affiliated Hospital of Zhengzhou University
Conditions:
Extracorporeal Membrane Oxygenation
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Heparin (regular or unfractionated heparin, not low molecular weight heparin) is given as a bolus (50-100 units per kilogram) at the time of extracorporeal membrane oxygenation(ECMO) cannulation, and ...
Detailed Description
Forty adult patients with cardiac or respiratory failure supported by ECMO are enrolled in the study. Patients are randomly allocated to be treated with either a) heparin has been stopped for 1 hour b...
Eligibility Criteria
Inclusion
- ECMO therapy was instituted to support circulatory and/or respiratory failure;
- Heparin continuous infusion for anticoagulation during ECMO;
- Native cardiac and pulmonary function improve,and the trial off is successful.
- Ensure each patient provides signed and dated informed consent.
Exclusion
- History of thrombotic diseases or coagulation disorder；
- Thrombosis or bleeding events occurred prior to allocation；
- Heparin stopped prior to allocation；
- Other anticoagulants, antiplatelets, hemostatics and other drugs affected coagulation function have been used；
- The trial off has failed;
- Pregnant and lactating patients;
- Patients participated in the other studies;
- Patients couldn't accept comprehensive treatment;
- Patients couldn't acquire informed consent;
Key Trial Info
Start Date :
February 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05239637
Start Date
February 15 2022
End Date
October 1 2023
Last Update
March 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General ICU of the second affiliated hospital of zhengzhou university
Zhengzhou, Henan, China, 450000